leadf
logo-loader
viewChampignon Brands Inc.

Champignon Brands says review of bipolar disorders confirms early diagnosis and treatment can improve patient quality of life

Champignon Brands CEO Dr Roger McIntyre has authored an article in The Lancet which provides an overview of bipolar disorders and treatment, while highlighting relevant clinical controversies

Champignon Brands Inc. - Champignon Brands says review of bipolar disorders confirms early diagnosis and treatment can improve patient quality of life
According to Dr McIntyre article, the next decade will see the 'testing of mechanistically novel agents for bipolar disorders'

Champignon Brands Inc (CSE:SHRM) (OTCQB:SHRMF), a research-driven company specializing in breakthrough ketamine treatment for depression and other mental health conditions, revealed Friday that CEO Dr Roger McIntyre’s article “Bipolar Disorders” has been published in the prestigious peer-reviewed The Lancet medical journal. 

The article is part of The Lancet's peer-reviewed seminars and provides a "state-of-the-art overview of bipolar disorders, covering epidemiology, parthenogenesis, diagnosis, treatment, and prevention, while highlighting relevant clinical controversies."

Bipolar disorders develop before the age of 25 in 70% of adults and substantially reduce the quality of life and psychosocial functioning across a person’s lifespan. Most individuals with bipolar disorders are affected by depressive symptoms and episodes. Nearly 1.25% of patients with major depressive disorder (MDD) per year are subsequently diagnosed with a bipolar disorder.

READ: Champignon Brands is making a scientific case for psychedelic medicine

Crucially, although people with bipolar disorders are 20-to-30 times more likely to die by suicide (around 30-to-50% of adults with bipolar disorders have a lifetime history of suicide attempts), suicide is not the primary reason people with the condition lose 10-to-20 potential years of life.

The article notes that lithium is a well-established antimanic agent that is also capable of attenuating depressive symptoms and reducing suicidal ideation. Other treatments for bipolar depression include cariprazine, lurasidone, quetiapine, and the combination of olanzapine–fluoxetine.

These treatments work best in individuals with fewer episodes and shorter illness durations. That is, patients who are diagnosed and receive effective treatment promptly are more likely to recover than are those who have already experienced multiple episodes and years of unstable illness.

Unfortunately, individuals with bipolar disorders are often misdiagnosed.

"Most individuals with bipolar disorders are not accurately diagnosed until approximately 6–10 years after first contact with a primary health-care provider, a specialty health-care provider, or both, despite having clinical characteristics of the illness," points out the article.

It concludes: "The availability of so-called rapid-onset treatments (e.g., ketamine) and treatments that could mitigate suicidality is crucial to clinical settings. The next decade will see the testing of mechanistically novel agents for bipolar disorders."

Champignon CEO Dr McIntyre is a Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network. He has published over 600 scientific articles on bipolar disorders and depression.

Champignon Brands works closely with subsidiaries including AltMed Capital Corp, which owns the Canadian Rapid Treatment Center of Excellence.

Contact the author Uttara Choudhury at [email protected]

Follow her on Twitter: @UttaraProactive

Quick facts: Champignon Brands Inc.

Price: 0.89 CAD

CSE:SHRM
Market: CSE
Market Cap: $70.54 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Champignon Brands Inc. named herein, including the promotion by the Company of Champignon Brands Inc. in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Champignon Brands charts course for success with acquisitions and a name change

Champignon Brands (CSE: SHRM- OTCQB: SHRMF) CEO Dr Roger McIntyre joined Steve Darling from Proactive Vancouver with news the company is changing its name to Apotheosis, which means the high point of development. McIntyre discusses the thinking behind the change, plus acquisitions and other...

on 06/22/2020

3 min read